Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-Negative Case-Control Design

View ORCID ProfileMatthew W Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina Mack, Stephen Toovey, View ORCID ProfileNancy A. Dreyer
doi: https://doi.org/10.1101/2022.01.06.22268726
Matthew W Reynolds
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew W Reynolds
  • For correspondence: matthew.reynolds@iqvia.com
Alex Secora
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Joules
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Albert
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Brinkley
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Kwon
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Mack
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Toovey
bPegasus Research, Neuschwaendistrasse 6, 6390 Engelberg, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy A. Dreyer
aIQVIA Real-World Solutions. 201 Broadway, Cambridge, MA 02139 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nancy A. Dreyer
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

It is important to assess the extent to which the real-world effectiveness of marketed vaccines is consistent with that observed in the clinical trials, and to characterize how well vaccines prevent COVID-19 symptoms. We conducted a modified test-negative design (TND) to evaluate the RW effectiveness of three COVID-19 vaccines by leveraging data from an on-going, US community-based registry. Vaccine effectiveness was examined in two ways: considering cases who (1) tested positive for COVID-19 (695 cases, 1,786 controls) and who (2) tested positive with at least one moderate/severe COVID-19 symptom (165 cases, 2,316 controls). Any vaccination (full or partial) was associated with a 95% reduction in the odds of having a positive COVID-19 test [adjusted odds ratio (aOR) = 0.05 (95% confidence interval (CI): 0.04, 0.06)]. Full vaccination was associated with an aOR of 0.03 (95% CI: 0.03, 0.05) while partial vaccination had an aOR of 0.08 (95% CI: 0.06, 0.12). Any vaccination was associated with a 71% reduction in the odds of testing positive and having at least one moderate/severe symptom (aOR=0.29 (95% CI: 0.20, 0.40)). High effectiveness was observed across all three vaccine manufacturers both for prevention of positive COVID-19 test results and prevention of moderate/severe COVID-19 symptoms.

Clinicaltrials.gov NCT04368065

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported in part by a contract with the US Food and Drug Administration. The bulk of the funding was provided by IQVIA

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Advarra gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Authors’ email addresses:

    Matthew.Reynolds{at}IQVIA.com

    Alex.Secora{at}IQVIA.com

    Alice.Joules{at}IQVIA.com

    Lisa.Albert{at}IQVIA.com

    Emma.Brinkley{at}IQVIA.com

    Tom.Kwon{at}IQVIA.com

    Christina.Mack{at}IQVIA.com

    Malaria{at}sunrise.ch [Stephen Toovey]

    Nancy.Dreyer{at}IQVIA.com

Data Availability

Due to data privacy and security regulations the researchers are not able to share participant level data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 06, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-Negative Case-Control Design
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-Negative Case-Control Design
Matthew W Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina Mack, Stephen Toovey, Nancy A. Dreyer
medRxiv 2022.01.06.22268726; doi: https://doi.org/10.1101/2022.01.06.22268726
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evaluating Real-World COVID-19 Vaccine Effectiveness Using a Test-Negative Case-Control Design
Matthew W Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina Mack, Stephen Toovey, Nancy A. Dreyer
medRxiv 2022.01.06.22268726; doi: https://doi.org/10.1101/2022.01.06.22268726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10550)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3979)
  • Radiology and Imaging (653)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)